Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Chinese Paediatric Post-operative NF1-PNs
NCT05825365Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in neurofibromatosis type 1 (NF1) comparing Selumetinib with Placebo (2 arms). Primary endpoint: Progression-Free Survival Rate at 2 years. Planned start Aug 2023; status: withdrawn.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT05825365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05825365.